Revenio as an investment

[JNivala]

@DayTraderXL

@JNivala

From that 80M figure, you can immediately wipe off -50% in one go. About half of glaucoma patients seem to be those whose intraocular pressure is never a problem.

Did you have any research sources to support that claim? You can also find different data here: home icare - Search Results - PMC

“Pressure is the most important risk factor. Glaucoma treatment mostly involves pressure management: medication/beta-blocker or laser, which makes holes in the eyes to improve fluid movement, or laser, which heats and improves fluid movement (e.g., micropulse)”

As a layman, one would think that monitoring pressure is precisely very important.

The Duodecim Handbook of Ophthalmology, for example. It’s professional literature, of course, so it probably won’t be openly available by Googling. I haven’t really delved into any global datasets; I trust that the figures in Finnish professional literature are at least roughly accurate.

Elevated intraocular pressure is the most important single risk factor, but it’s good to note that the Finnish name for glaucoma, “silmänpainetauti” (pressure-eye disease), is quite misleading. Glaucoma is a disease of the optic nerve, and some 50 different “disease forms” have already been identified – some of these are associated with elevated pressures, others are not.

Thanks @Juha_Kinnunen for the good answers as always It was new to me that Revenio’s imaging devices are competitive even in terms of price with those margins, if one only considers customer costs. I would still like to ask if this information, e.g., about DSRplus’s lower price compared to its competitors, came directly from Revenio’s management or from where?